Prevention of second primary tumors by an acyclic retinoid, polyprenoic acid, in patients with hepatocellular carcinoma

New England Journal of Medicine

Volumn 334, Issue 24, 1996, Pages 1561-1565

  Muto, Yasutoshi ^a   Moriwaki, Hisataka ^a   Ninomiya, Mitsuo ^d   Adachi, Sadashi ^a   Saito, Akiko ^b   Takasaki, Ken Takeshi ^b   Tanaka, Takuji ^a   Tsurumi, Kaito ^a   Okuno, Masataka ^a   Tomita, Eiichi ^c   Nakamura, Toshiyuki ^e   Kojima, Takao ^f  

^a GIFU UNIVERSITY   (Japan)

^b TOKYO WOMEN'S MEDICAL UNIVERSITY   (Japan)

^c Gifu Municipal Hospital   (Japan)

^d Gihoku General Hospital   (Japan)

^e Gifu Red Cross Hospital   (Japan)

^f ASAHI UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

POLYPRENOIC ACID;

ARTICLE; CANCER PREVENTION; CANCER RECURRENCE; CANCER SURGERY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; HUMAN; LIVER CARCINOGENESIS; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

AGED; CARCINOMA, HEPATOCELLULAR; EMBOLIZATION, THERAPEUTIC; ETHANOL; FEMALE; FOLLOW-UP STUDIES; HUMANS; INJECTIONS, INTRALESIONAL; LIVER NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASMS, SECOND PRIMARY; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; SURVIVAL ANALYSIS; TREATMENT OUTCOME; TRETINOIN;

EID: 5844370499     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/nejm199606133342402     Document Type: Article

References (67)

1. Sporn MB, Newton DL. Chemoprevention of cancer with retinoids. Fed Proc 1979;38:2528-34.
2. Sporn MB. Carcinogenesis and cancer: different perspectives on the same disease. Cancer Res 1991;51:6215-8.
3. Moon RC, Mehta RG, Rao KVN. Retinoids and cancer in experimental animals. In: Sporn MB, Roberts AB, Goodman DS, eds. The retinoids: biology, chemistry, and medicine. 2nd ed. New York: Raven Press, 1994:573-95.
4. Boone CW, Kelloff GJ, Malone WE. Identification of candidate cancer chemopreventive agents and their evaluation in animal models and human clinical trials: a review. Cancer Res 1990;50:2-9.
5. Hong WK, Itri LM. Retinoids and human cancer. In: Sporn MB, Roberts AB, Goodman DS, eds. The retinoids: biology, chemistry, and medicine. 2nd ed. New York: Raven Press, 1994:597-630.
6. Blot WJ, Li JY, Taylor PR, et al. Nutrition intervention trials in Linxian, China: supplementation with specific vitamin/mineral combinations, cancer incidence, and disease-specific mortality in the general population. J Natl Cancer Inst 1993;85:1483-92.
7. The Alpha-Tocopherol, Beta Carotene Cancer Prevention Study Group. The effect of vitamin E and beta carotene on the incidence of lung cancer and other cancers in male smokers. N Engl J Med 1994;330:1029-35.
8. Greenberg ER, Baron JA, Tosteson TD, et al. A clinical trial of antioxidant vitamins to prevent colorectal adenoma. N Engl J Med 1994;331:141-7.
9. Hong WK, Lippman SM, Itri LM, et al. Prevention of second primary tumors with isotretinoin in squamous-cell carcinoma of the head and neck. N Engl J Med 1990;323:795-801.
10. Muto Y, Moriwaki H, Omori M. In vitro binding affinity of novel synthetic polyprenoids (polyprenoic acids) to cellular retinoid-binding proteins. Jpn J Cancer Res [Gann] 1981;72:974-7.
11. Muto Y, Moriwaki H. Antitumor activities of vitamin A and its derivatives. J Natl Cancer Inst 1984;73:1389-93.
12. Moriwaki H, Muto Y, Ninomiya M, Kawai K, Suzuki Y, Seto T. Inhibitory effects of synthetic acidic retinoid and polyprenoic acid on the development of hepatoma in rats induced by 3′-methyl-N,N-dimethyl-4-aminoazobenzene. J Gastroenterol 1988;23:546-52.
13. Muto Y, Kawai K, Moriwaki H. Antitumor activity of a novel synthetic polyprenoic acid (E-5166) on 'spontaneous' hepatic tumors of C3H/HeNCrj mice. In: Saurai JH, ed. Retinoids: new trends in research and therapy. Basel, Switzerland: Karger, 1985:293-7.
14. Fukutomi Y, Omori M, Muto Y, Ninomiya M, Okuno M, Moriwaki H. Inhibitory effects of acyclic retinoid (polyprenoic acid) and its hydroxy derivative on cell growth and on secretion of alpha-fetoprotein in human hepatoma-derived cell line (PLC/PRF/5). Jpn J Cancer Res [Gann] 1990; 81:1281-5.
15. Yamada Y, Shidoji Y, Fukutomi Y, et al. Positive and negative regulations of albumin gene expression by retinoids in human hepatoma cell lines. Mol Carcinog 1994;10:151-8.
16. Muto Y, Moriwaki H. Acyclic retinoids and cancer chemoprevention. Pure Appl Chem 1991;63:157-60.
17. Liver Cancer Study Group of Japan. Survey and follow-up study of primary liver cancer in Japan: report 11. Acta Hepatol Jpn 1995;36:208-18.
18. Kita K, Ebara M, Sugiura N, Ohto M. Percutaneous ethanol injection (PEI) for small hepatocellular carcinoma - study on its therapeutic effect and prognosis based on long-term observation. Nippon Shokakibyo Gakkai Zasshi 1994;91:1946-55. (In Japanese.)
19. Shirabe K, Kanematsu T, Matsumata T, Adachi E, Akazawa K, Sugimachi K. Factors linked to early recurrence of small hepatocellular carcinoma after hepatectomy: univariate and multivariate analysis. Hepatology 1991;14: 802-5.
20. Yamasaki S, Hasegawa H, Takayama T, et al. Clinicopathological features of recurrent primary liver cancer in Japan. In: Okuda K, ed. Primary liver cancer in Japan. Tokyo, Japan: Springer-Verlag, 1992:345-51.
21. Ikeda K, Saitoh S, Tsubota A, et al. Risk factors for tumor recurrence and prognosis after curative resection of hepatocellular carcinoma. Cancer 1993;71:19-25.
22. Ohto M, Ebara M, Watanabe Y, et al. Percutaneous ethanol injection therapy (PEI) for small hepatocellular carcinoma: evaluation of its utility on the basis of tumor-images and survival after therapy. Jpn J Med Imaging 1988; 7:25-33.
23. Ebara M, Ohto M, Sugiura N, et al. Percutaneous ethanol injection for the treatment of small hepatocellular carcinoma: study of 95 patients. J Gastroenterol Hepatol 1990;5:616-26.
24. Liver Cancer Study Group of Japan. The general rules for the clinical and pathological study of primary liver cancer. 3rd ed. Tokyo, Japan: Kanehara, 1992:20-6. (In Japanese.)
25. Gehan EA. A generalized Wilcoxon test for comparing arbitrarily singlycensored samples. Biometrika 1965;52:203-23.
26. Warren S, Gates O. Multiple primary malignant tumors: a survey of the literature and a statistical study. Am J Cancer 1932;16:1358-414.
27. Sakamoto M, Hirohashi S, Tsuda H, Shimosato Y, Makuuchi M, Hosoda Y. Multicentric independent development of hepatocellular carcinoma revealed by analysis of hepatitis B virus integration pattern. Am J Surg Pathol 1989;13:1064-7.
28. Esumi M, Aritaka T, Arii M, et al. Clonal origin of human hepatoma determined by integration of hepatitis B virus DNA. Cancer Res 1986;46:5764-71.
29. Tsuda H, Hirohashi S, Shimosato Y, Terada M, Hasegawa H. Clonal origin of atypical adenomatous hyperplasia of the liver and clonal identity with hepatocellular carcinoma. Gastroenterology 1988;95:1664-6.
30. The Liver Cancer Study Group of Japan. Predictive factors for long term prognosis after partial hepatectomy for patients with hepatocellular carcinoma in Japan. Cancer 1994;74:2772-80.
31. Edmondson HA, Steiner PE. Primary carcinoma of the liver: a study of 100 cases among 48,900 necropsies. Cancer 1954;7:462-503.
32. Yamanaka M, Okamoto E, Toyosaka A, et al. Prognostic factors after hepatectomy for hepatocellular carcinomas: a univariate and multivariate analysis. Cancer 1990;65:1104-10.
33. Belghiti J, Parus Y, Farges O, Benhamou JP, Fekete F. Intrahepatic recurrence after resection of hepatocellular carcinoma complicating cirrhosis. Ann Surg 1991;214:114-7.
34. Nagao T, Inoue S, Yoshimi F, et al. Prospective recurrence of hepatocellular carcinoma. Ann Surg 1990;211:28-33.
35. Jwo SC, Chiu JH, Chau GY, Loong CC, Lui WY. Risk factors linked to tumor recurrence of human hepatocellular carcinoma after hepatic resection. Hepatology 1992:16:1367-71.
36. Sugioka T, Tsuzuki T, Kanai T. Postresection prognosis of patients with hepatocellular carcinoma. Surgery 1993;113:612-8.
37. Nagasue N, Uchida M, Makino Y, et al. Incidence and factors associated with intrahepatic recurrence following resection of hepatocellular carcinoma. Gastroenterology 1993;105:488-94.
38. Matsumata T, Kanematsu T, Takenaka K, Yoshida Y, Nishizaki T, Sugimachi K. Patterns of intrahepatic recurrence after curative resection of hepalocellular carcinoma. Hepatology 1989;9:457-60.
39. Arii S, Tanaka J, Yamazoe Y, et al. Predictive factors for intrahepatic recurrence of hepatocellular carcinoma after partial hepatectomy. Cancer 1992; 69:913-9.
40. Nagasue N, Kohno H, Chang YC, et al. Liver resection for hepatocellular carcinoma: result of 229 consecutive patients during 11 years. Ann Surg 1993;217:375-84.
41. Chiu JH, Wu LH, Kao HL, et al. Can determination of the proliferative capacity of the nontumor portion predict the risk of tumor recurrence in the liver remnant after resection of human hepatocellular carcinoma? Hepatology 1993;18:96-102. [Erratum, Hepatology 1993;18:1292.]
42. Adachi E, Maeda T, Matsumata T, et al. Risk factors for intrahepatic recurrence in human small hepatocellular carcinoma. Gastroenterology 1995; 108:768-75.
43. Japanese Red Cross Non-A, Non-B Hepatitis Research Group. Effect of screening for hepatitis C virus antibody and hepatitis B virus core antibody on incidence of post-transfusion hepatitis. Lancet 1991 ;338:1040-1.
44. Kiyosawa K, Sodeyama T, Tanaka E, et al. Intrafamilial transmission of hepatitis C virus in Japan. J Med Virol 1991;33:114-6.
45. Health and Welfare Statistics Association. Annual report of disease-related deaths in Japan. J Health Welfare Stat 1994;41:Suppl 9:47-60.
46. Shinagawa T, Ohto M, Kimura K, et al. Diagnosis and clinical features of small hepatocellular carcinoma with emphasis on the utility of real-time ultrasonography: a study in 51 patients. Gastroenterology 1984;86:495-50 2.
47. Ebara M, Ohto M, Kondo F. Strategy for early diagnosis of hepatocellular carcinoma (HCC). Ann Acad Med Singapore 1989;18:83-9.
48. Slaughter DP, Southwick HW, Smejkal W. "Field cancerization" in oral stratified squamous epithelium: clinical implications of multicentric origin. Cancer 1953;6:963-8.
49. Chen PJ, Chen DS, Lai MY, et al. Clonal origin of recurrent hepatocellular carcinomas. Gastroenterology 1989;96:527-9.
50. Kiyosawa K, Sodeyama T, Tanaka E, et al. Interrelationship of blood transfusion, non-A, non-B hepatitis and hepatocellular carcinoma: analysis by detection of antibody to hepatitis C virus. Hepatology 1990; 12:671-5.
51. Armstrong RB, Ashenfelter KO, Eckhoff C, Levin AA, Shapiro SS. General and reproductive toxicology of retinoids. In: Sporn MB, Roberts AB, Good-man DS, eds. The retinoids: biology, chemistry, and medicine. 2nd ed. New York: Raven Press, 1994:545-72.
52. Muto Y, Omori M, Sugawara K. Demonstration of a novel cellular retinol-binding protein, F-type, in hepatocellular carcinoma. Jpn J Cancer Res [Gann] 1979;70:215-22.
53. Moriwaki H, Muto Y, Ninomiya M, Shimizu M, Takahashi Y. Time course of changes in cellular retinoid-binding proteins in liver hyperplastic nodules and hepatocellular carcinoma experimentally induced in rats. Acta Hepatol Jpn 1982;23:523-9.
54. Muto Y, Omori M. A novel cellular retinoid-binding protein, F-type, in hepatocellular carcinoma. Ann N Y Acad Sci 1981;359:91 -103.
55. Yu M-W, Hsieh H-H, Pan W-H, Yang C-S, Chen C-J. Vegetable consumption, serum retinol level, and risk of hepatocellular carcinoma. Cancer Res 1995;55:1301-5.
56. Daoud AH, Griffin AC. Effect of retinoic acid, butylated hydroxytoluene, selenium, and sorbic acid on azo-dye hepatocarcinogenesis. Cancer Lett 1980;9:299-304.
57. Mack DO, Reed VL, Smith LD. Retinyl acetate inhibition of 3′-methyl-4-dimethyl-aminoazobenzene induced hepatic neoplasia. Int J Biochem 1990;22:359-65.
58. Curphey TJ, Kuhlman ET, Roebuck BD, Longnecker DS. Inhibition of pancreatic and liver carcinogenesis in rats by retinoid- and selenium-supplemented diets. Pancreas 1988;3:36-40.
59. Baba M, Iishi H, Yamamoto R, Tatsuta M. Inhibition by retinoic acid of hepatocarcinogenesis induced by N-nitrosomorpholine and of expression of myc oncogene protein in Sprague-Dawley rats. Im J Cancer 1991;49:467-70.
60. Maiorana A, Gullino PM. Effect of retinyl acetate on the incidence of mammary carcinomas and hepatomas in mice. J Natl Cancer Inst 1980;64:655-63.
61. Tsurumi H, Tojo A, Takahashi T, et al. Differentiation induction of human promyelocytic leukemia cells by acyclic retinoid (polyprenoic acid). Int J Hematol 1993;59:9-15.
62. Nakamura N, Shidoji Y, Yamada Y, Hatakeyama H, Moriwaki H. Muto Y. Induction of apoptosis by acyclic retinoid in the human hepatoma-derived cell line, HuH-7. Biochem Biophys Res Commun 1995;207.382-8.
63. Sato Y, Nakata K, Kato Y, et al. Early recognition of hepatocellular carcinoma based on altered profiles of alpha-fetoprotein. N Engl J Med 1993; 328:1802-6.
64. Taketa K, Endo Y, Sekiya C, et al. A collaborative study for the evaluation of lectin-reactive alpha-fetoproteins in early detection of hepatocellular carcinoma. Cancer Res 1993;53:5419-23.
65. Shiraki K, Takase K, Tameda Y, Hamada M, Kosaka Y, NakanoT. A clinical study of lectin-reactive alpha-fetoprotein as an early indicator of hepatocellular carcinoma in the follow-up of cirrhotic patients. Hepatology 1995;22: 802-7.
66. Araki H, Shidoji M, Yamada Y, Moriwaki H, Muto Y, Retinoid agonist activities of synthetic geranyl geranoic acid derivatives. Biochem Biophys Res Commun 1995;209:66-72.
67. Hatakeyama H, Shidoji Y, Omori M, et al. Retardation effect of acyclic retinoid on spontaneous hepatocarcinogenesis without changes in incidence of c-Ha-ras mutations in C3H/HeNCrj mice. Center Detect Prev (in press).